ITMCTR2100005201招募中1 期
Clinical efficacy evaluation of Guanxinning tablet in the prevention and treatment of hypertension and Coronary heart disease complicated with heart failure
Shenzhen Luohu People's Hospital0 个研究点开始时间: 待定最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 招募中
- 发起方
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional study
入排标准
- 性别
- All
入选标准
- •(1) Meet the diagnostic criteria for chronic heart failure of coronary heart disease, and belong to stage B, NYHA grade I or stage C, NYHA grade II-III;
- •(2) The thickness of the interventricular septum (IVS) obtained by echocardiography> 11mm;
- •(3) Diagnosed as mild to moderate essential hypertension (grade 1 or 2 essential hypertension);
- •Diastolic blood pressure and systolic blood pressure in the consulting room without the influence of drugs need to meet the following conditions: ?Measured by sitting blood pressure (average of 3 measurements): 90mmHg=average diastolic blood pressure<110 mmHg and/or ?Measured by sitting blood pressure (taken from 3 measurements) Average): 140mmHg=average systolic blood pressure<180mmHg;
- •(4) Both men and women are between 18 and 80 years old;
- •(5) Accept the drug treatment voluntarily and sign an informed consent form.
排除标准
- •(1) Severe essential hypertension (sitting systolic blood pressure =180 mmHg and/or sitting diastolic blood pressure =110mmHg) and poor drug control, malignant hypertension, hypertensive emergency, hypertensive crisis, hypertensive encephalopathy, etc.; Known secondary hypertension;
- •(2) The condition was unstable within 4 weeks before enrollment (such as hospitalization due to aggravated heart failure and confirmed by records); myocardial infarction or coronary revascularization occurred within 2 months before enrollment; Stroke; paroxysmal atrial fibrillation occurred within 4 weeks before enrollment and the drug dose for atrial fibrillation treatment was not stable, or permanent atrial fibrillation or atrial flutter;
- •(3) Patients with other heart diseases: pulmonary heart disease, congenital heart disease, moderate to severe pulmonary hypertension, moderate to severe stenosis or regurgitation of the heart valve, or severe aortic regurgitation, cardiomyopathy, and heart failure caused by arrhythmia; heartbeat Tachy attacks or cardiogenic shock, unstable angina pectoris, uncontrollable malignant arrhythmia; those undergoing cardiothoracic surgery, the subject has a planned left ventricular remodeling operation, a history of heart transplantation or a planned heart transplantation Technique
- •(4) Active tuberculosis;
- •(5) Autoimmune diseases, such as systemic lupus erythematosus and giant cell myocarditis;
- •(6) There is a history of any malignant tumor;
- •(7) Obesity, body mass index (BMI)> 30kg/m2;
- •(8) Patients with abnormal liver and kidney function indexes (ALT, AST, Scr exceed the upper limit of the normal reference range by 2 times; GFR=60ml/(min·1.73m2));
- •(9) Use other traditional Chinese medicines for promoting blood circulation and removing blood stasis, or use anticoagulant drugs, such as warfarin. The specific combination of drugs should be based on the actual clinical needs of the investigator;
- •(10) People with allergies, or allergies to multiple drugs and foods, or patients who are known to be allergic to the research drug (including its ingredients);
- •(11) Those who have pregnancy plans or are pregnant or lactating women, or those who cannot guarantee effective contraception during the trial period;
- •(12) Mental illness with poor control of the condition and drug users who have not given up drugs;
- •(13) Patients who participated in other clinical trials within the past 3 months;
- •(14) The investigator believes that there are patients with unsuitable factors for selection.
研究者
相似试验
招募中
1 期
Clinical study of guanxining tablet in the treatment of rheumatoid arthritis with cardiovascular damageSystemic lupus erythematosusITMCTR2000003055Zhejinag University of f Chinese Medicine
尚未招募
4 期
Evaluation of the clinical efficacy of Guanxinning tablets in the treatment of patients with carotid atherosclerotic plaqueCarotid atherosclerotic plaque formationITMCTR2100005440Dongzhimen Hospital, Beijing University of Chinese Medicine
尚未招募
4 期
Effectiveness of Guanxinning Tablet on the Stable Coronary Artery Disease based on the Real World: A Multi-center Registration StudyITMCTR1900025340Xiyuan Hospital, CACMS
尚未招募
1 期
Clinical study on efficacy and safety of Huangqi Guizhi Wuwu decoction bubble bag in paclitaxel related peripheral neuritis of breast cancer patients : A protocol for a randomized, controlled, double-blind trialBreast CancerITMCTR2200006006ational Cancer Center, Chinese Academy of Medical Sciences / Cancer Hospital of Peking Union Medical College
尚未招募
4 期
Study on the Safety and Effectiveness of Guanxinning Tablets in Intensive Therapy for Patients with Acute Coronary SyndromeAcute Coronary SyndromeITMCTR2100005434Hangzhou First People's Hospital